Results 101 to 110 of about 287,154 (333)

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells [PDF]

, 2021
Takumi Itoh, Ryo Hatano, Yoshiya Horimoto, Taketo Yamada, Dan Song, Haruna Otsuka, Yûki Shirakawa, Shuji Mastuoka, Noriaki Iwao, Thomas M. Aune, Nam H. Dang, Yutaro Kaneko, Ko Okumura, Chikao Morimoto, Kei Ohnuma   +14 more
openalex   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report [PDF]

, 2023
Pierluigi di Mauro, Greta Schivardi, Rebecca Pedersini, Lara Laini, Andrea Esposito, Vito Amoroso, Marta Laganà, Salvatore Grisanti, Deborah Cosentini, Alfredo Berruti   +9 more
openalex   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

PLoS ONE, 2015
PurposeThis study sought to assess the prevalence of common germline mutations in several genes engaged in the repair of DNA double-strand break by homologous recombination in patients with triple-negative breast cancers and hereditary non-triple ...
Pawel Domagala, Anna Jakubowska, Katarzyna Jaworska-Bieniek, Katarzyna Kaczmarek, Katarzyna Durda, Agnieszka Kurlapska, Cezary Cybulski, Jan Lubinski   +7 more
doaj   +1 more source

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated -Driven Proliferation in Triple-Negative Breast Cancer

Breast Cancer: Basic and Clinical Research, 2020
Background: Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly understood and lacks any targeted therapy, which makes it difficult to treat.
Akanksha Mishra, Maria Bonello, Adam Byron, Simon P Langdon, Andrew H Sims   +4 more
doaj   +1 more source

Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer [PDF]

, 2017
1.7 million cases of breast cancer are diagnosed every year with 522,000 deaths. Molecular classifications of breast cancer have resulted in improved treatments. However, treatments for triple negative breast cancer (TNBC) are lacking.
Edwards, Joanne, Liew, Benjamin, Lim, Zhi, Mallon, Elizabeth A., McCall, Pamela, Roseweir, Antonia K., Scott, Alison   +6 more
core   +2 more sources

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]

, 2013
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique, Denys, Hannelore, KRUSE, VIBEKE, Van Belle, Simon, Van den Broecke, Rudy   +4 more
core   +2 more sources

Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer [PDF]

, 2023
Xiaopeng Hao, Xianqi Gao, Shanshan Yin, Zefei Jiang   +3 more
openalex   +1 more source